Compare · BJDX vs RMD
BJDX vs RMD
Side-by-side comparison of Bluejay Diagnostics Inc. (BJDX) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BJDX and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.69B, about 11556.4x BJDX ($2.9M).
- RMD has been more active in the news (12 items in the past 4 weeks vs 6 for BJDX).
- RMD has more recent analyst coverage (25 ratings vs 1 for BJDX).
- Company
- Bluejay Diagnostics Inc.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $2.9M
- $33.69B
- 1M return
- -
- -1.16%
- 1Y return
- -
- -2.13%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 12
- Recent ratings
- 1
- 25
Bluejay Diagnostics Inc.
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest BJDX
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
- SEC Form 8-K filed by Bluejay Diagnostics Inc.
- Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
- SEC Form 8-K filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
Latest RMD
- Chairman and CEO Farrell Michael J. covered exercise/tax liability with 8,111 units of ResMed Common Stock, decreasing direct ownership by 2% to 471,774 units (SEC Form 4) (tax withholding)
- Chief Financial Officer Bloomer Aaron covered exercise/tax liability with 1,095 units of ResMed Common Stock, decreasing direct ownership by 12% to 7,977 units (SEC Form 4) to satisfy withholding tax
- Director Farrell Peter C covered exercise/tax liability with 169 units of ResMed Common Stock, decreasing direct ownership by 0.33% to 51,634 units (SEC Form 4) (withholding obligation)
- Director De Witte Jan covered exercise/tax liability with 60 units of ResMed Common Stock, decreasing direct ownership by 1% to 4,201 units (SEC Form 4) (for tax liability)
- Director Gill Harjit covered exercise/tax liability with 36 units of ResMed Common Stock, decreasing direct ownership by 0.33% to 10,904 units (SEC Form 4) (withholding tax)
- Global General Counsel Rider Michael J covered exercise/tax liability with 1,944 units of ResMed Common Stock, decreasing direct ownership by 16% to 10,417 units (SEC Form 4) (withholding obligation)
- Chairman and CEO Farrell Michael J. exercised 4,993 units of ResMed Common Stock at a strike of $146.34 and sold $1,175,089 worth of ResMed Common Stock (4,993 units at $235.35) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed downgraded by Canaccord Genuity
- SEC Form 10-Q filed by ResMed Inc.
- SEC Form 8-K filed by ResMed Inc.